M42 Invests In UK-Based Biotech Juvenescence

M42, the Abu Dhabi-based tech-enabled global health company specializing in artificial intelligence (AI), advanced technology, and genomics, announced an investment and strategic partnership with UK-based Juvenescence, a longevity-focused biotechnology company.

M42 was launched by G42 Healthcare, the healthcare arm of the UAE's global AI and cloud computing company, G42, and Mubadala Health, the healthcare arm of the Abu Dhabi-based sovereign wealth fund, Mubadala, in 2023.  

The announcement was made during Abu Dhabi Global Health Week (ADGHW), which was held at the Abu Dhabi National Exhibition Centre (ADNEC) from April 15 to 17. As part of this investment, M42 will establish a partnership with Juvenescence aimed at developing a pipeline of AI-powered therapeutics to promote healthy longevity and improve treatments for serious disease. 

The collaboration supports M42’s expanded focus on drug discovery through its new Integrated Health Solutions and Life Sciences platforms. By combining M42’s strengths in genomics and clinical trials with Juvenescence’s AI and drug development expertise, it aims to accelerate breakthroughs and fast-track clinical research. The partnership will also pursue research and development collaborations with leading global institutions and support M42’s biotech strategy in Abu Dhabi. A joint steering committee of senior executives from both companies will oversee its execution. 

In a statement about the investment, Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, said, “With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi’s push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges. With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it’s about impact – on lives, on science and on the future of health.” 

Dr Fahed Al Marzooqi, Chief Executive Officer of M42’s Integrated Health Solutions platform and Acting Chief Executive Officer of M42’s AI Life Sciences platform, added, “Our partnership with Juvenescence is a crucial step toward redefining healthcare through AI-driven drug discovery and biotechnology. By uniting AI innovation with biotech expertise, we’re not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress—delivering transformative therapies from Abu Dhabi to the world.” 

Additionally, Dr. Richard Marshall, Chief Executive Officer at Juvenescence, commented, “We are delighted to be working together with M42. This powerful partnership will combine M42’s expertise in AI, technology, and genomics with Juvenescence’s unrivalled ability to discover and develop innovative drugs for age-related disease. Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the healthspan of patients globally.” 

The collaboration will bring together Juvenescence’s team of scientists and industry experts—who collectively have over 150 years of experience in drug discovery and development—with M42, to help build its own pipeline of innovative therapeutics. 

Through this partnership, M42 strengthens its genomics capabilities, developed alongside the Department of Health Abu Dhabi (DoH), to advance precision medicine and deepen disease understanding. Its Omics Center of Excellence—the largest outside the U.S.—supports the Emirati Genome Project, which has sequenced over 800,000 genomes to date, from a target of one million. Meanwhile, the Abu Dhabi Biobank has collected over 900,000 samples, creating a powerful resource for future biomedical research. 

The partnership also supports Abu Dhabi’s broader vision of becoming a global hub for health innovation and life sciences as part of its economic diversification strategy. 

The Juvenescence leadership team includes CEO Richard Marshall, along with Jim Mellon, Deputy Chair and Founder of the Longevity Forum; Dr. Greg Bailey, Executive Chair; Dr. Declan Doogan, Director; Gillian Dines, Chief Scientific Officer; and Dr. Steve Felstead, Chief Medical Officer. Collectively, their development team has played a key role in bringing medicines to market that have generated over US$30 billion in peak annual sales. 

Co-founders Jim Mellon, Greg Bailey, and Declan Doogan—who have invested nearly $100 million into Juvenescence—have led two of the ten largest biopharma deals of the past decade. This includes the $11.6 billion acquisition of Biohaven by Pfizer in 2022, after initially acquiring a 54 percent stake for just $3.5 million. They also helped finance Medivation, later sold to Pfizer for $14.3 billion, achieving over 200x returns. 

Pictures in the lead image from left to right are Dr. Richard Marshall, Chief Executive Officer at Juvenescence, Dr. Fahed Al Marzooqi, Chief Executive Officer of M42’s Integrated Health Solutions platform and Acting Chief Executive Officer of M42. Courtesy of Juvenescence.